My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Humanigen (HGEN)
NASDAQ:HGEN
HGEN nasdaq
United States
Humanigen

Humanigen Stock Analysis & Ratings

Humanigen Stock Analysis Overview

Smart Score
1
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Humanigen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

HGEN

HGEN Stock Stats

Previous Close$6.53
Open$6.38
Bid0 x 0
Ask0 x 0
Today’s Range$6.19 - $6.45
52-Week Range$5.68 - $29.20
Volume1.65M
Average Volume1.99M
Market Cap$381.39M
Beta2.66
P/E Ratio-1.7
EPS-3.79
Earnings DateNov 18, 2021

Company Description

Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Cameron Durrant
Employees
5
ISIN
US4448632038
Address
533 Airport Boulevard, Burlingame, CA, 94005, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

Humanigen News


HGEN FAQ

What was Humanigen’s price range in the past 12 months?
Humanigen lowest stock price was $5.68 and its highest was $29.20 in the past 12 months.
    What is Humanigen’s market cap?
    Humanigen’s market cap is $381.39M.
      What is Humanigen’s price target?
      The average price target for Humanigen is $19.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $28.00 ,the lowest forecast is $9.00. The average price target represents 202.18% Increase from the current price of $6.42.
        What do analysts say about Humanigen?
        Humanigen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Humanigen’s upcoming earnings report date?
          Humanigen’s upcoming earnings report date is Nov 18, 2021 which is in 24 days.
            How were Humanigen’s earnings last quarter?
            Humanigen released its earnings results on Aug 12, 2021. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of -$0.862 by -$0.338.
              Is Humanigen overvalued?
              According to Wall Street analysts Humanigen’s price is currently Undervalued.
                Does Humanigen pay dividends?
                Humanigen does not currently pay dividends.
                What is Humanigen’s EPS estimate?
                Humanigen’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Humanigen have?
                Humanigen has 59,410,000 shares outstanding.
                  What happened to Humanigen’s price movement after its last earnings report?
                  Humanigen reported an EPS of -$1.2 in its last earnings report, missing expectations of -$0.862. Following the earnings report the stock price went down -0.821%.
                    Which hedge fund is a major shareholder of Humanigen?
                    Currently, no hedge funds are holding shares in HGEN

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis